updated 9/2/2010 4:19:28 PM ET 2010-09-02T20:19:28

NEW YORK, Sept. 2, 2010 (GLOBE NEWSWIRE) -- Regenicin, Inc. (OTCBB:WDSTD), a clinical-stage biotechnology company, announced today that it will hold a media and investor conference at the NASDAQ MarketSite on Tuesday, September 14, 2010 at 1pm EDT. CEO Randy McCoy, senior executives and board members will be present.

This conference follows on Regenicin's recent announcement of the appoint of Amgen Co-founder Dr. Joseph Rubinfeld to their Board of Directors.

When: September 14, 2010, 1:00 pm EDT

Where: NASDAQ MarketSite, 4 Times Square, New York, NY   (43th and Broadway)

RSVP required for building security: Call 212.691.8000 or email strell@sunshinesachs.com

Mr. McCoy and his team will be available for interviews prior and post conference. Please contact Jay Strell, strell@sunshinesachs.com or 212.691.8000. 

About Regenicin

Regenicin, Inc. is a development-stage company focusing on next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin. It is devoted to the discovery, development, manufacture and marketing of innovative, high-technology therapies and products for the wound care, tissue regeneration and therapeutic support system markets with PermaDerm, which is the only tissue-engineered skin prepared from a patient's own skin cells. The company is headquartered in New York, NY.

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com